Key facts
- Eli Lilly raised its full-year revenue forecast to $91 billion to $92 billion.
- Third-quarter revenue of $24.4 billion beat analyst expectations of $22.61 billion.
- Third-quarter adjusted profit of $7.48 per share beat estimates of $6.26.
- Sales of diabetes drug Mounjaro reached $10.72 billion.
- Obesity injection Zepbound sales were $5.35 billion.
- The company trimmed its profit outlook to $35.00 to $36.00 per share due to $4.57 per share in acquired research charges.
Eli Lilly raised its full-year revenue forecast to $91 billion to $92 billion and beat third-quarter earnings expectations on Thursday, driven by strong sales of its injectable weight-loss drugs Mounjaro and Zepbound. The company trimmed its profit outlook to $35.00 to $36.00 per share due to $4.57 per share in acquired research charges from recent deals. Third-quarter revenue reached $24.4 billion, surpassing analyst expectations of $22.61 billion, while adjusted profit of $7.48 per share exceeded estimates of $6.26. Sales of Mounjaro were $10.72 billion and Zepbound sales were $5.35 billion.